

Cancer treatment—other cancer treatment, text [X(150)]

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at <https://creativecommons.org/licenses/by/4.0/>.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Cancer treatment—other cancer treatment, text [X(150)]

Identifying and definitional attributes

Metadata item type:	Data Element
Short name:	Other cancer treatment
METEOR identifier:	403836
Registration status:	Health , Superseded 08/05/2014
Definition:	The cancer-directed treatment administered during the initial course of treatment for cancer, other than surgery, radiotherapy or systemic therapy, as represented by text.
Data Element Concept:	Cancer treatment—other cancer treatment
Value Domain:	Other cancer treatment text X[X(149)]

Value domain attributes

Representational attributes

Representation class:	Text
Data type:	String
Format:	X[X(149)]
Maximum character length:	150

Source and reference attributes

Submitting organisation:	Cancer Australia
---------------------------------	------------------

Data element attributes

Collection and usage attributes

Guide for use: This data item is to record cancer-directed treatments that cannot be appropriately assigned to the specific treatment codes in the cancer treatment data items for surgery, radiotherapy, systemic therapy agents and systemic therapy procedures.

Cancer-directed treatments refer to those treatments that destroy or modify cancer tissue anywhere in the body. The exception to this is treatments for hematopoietic diseases (refer to additional notes below).

Cancer-directed treatments may be palliative (to control symptoms, alleviate pain, or make the patient more comfortable) or curative.

Record all other treatments administered during the initial course of treatment. The initial course of treatment includes all treatments administered to the patient from diagnosis and before disease progression or recurrence.

Each treatment event delivered to the patient should be recorded; multiple entries are permitted.

Record antibody treatments, vaccine treatments, and those targeted therapies that use drugs or substances other than chemotherapy agents in this data item. Targeted therapies using chemotherapy agents are recorded in the data items for chemotherapy. Targeted therapies are treatments that use drugs or other substances to identify and attack specific cancer cells.

Do not record ancillary drugs. For example, allopurinol, which is commonly used as prophylaxis with chemotherapy agents to prevent severe hyperuricemia. A list of drugs regarded as ancillary is available in the SEER*Rx-Interactive Antineoplastic Drugs Database Version 1.4.1.

Treatment events may include (for example):

- Treatment unique to hematopoietic diseases, for example, phlebotomy, transfusions or aspirin. ONLY record aspirin therapy used to thin the blood for symptomatic control of thrombocythemia. Do not record aspirin used for pain or cardiovascular protection.
- Embolisation that is performed using alcohol as an embolising agent or for embolisation to a site other than the liver where the embolising agent is unknown. Embolisation using chemotherapeutic agents is coded separately with chemotherapy, and embolisation using a radioactive agent or seeds is coded with brachytherapy-radiation treatment.
- Any experimental or newly developed treatment that cannot be appropriately assigned to other specific treatment data items.
- A double-blind clinical trial. Record the treatment actually administered to the patient in the appropriate treatment data item when the double-blind trial code is broken.
- Cancer treatments administered by non-medical personnel. This includes unconventional methods whether administered as single therapy or in combination with conventional therapies. Record alternative therapies only if the patient doesn't receive any other type of treatment.

Collection methods: The information should be obtained from the patient's medical record.

Comments: Information on other cancer treatments is used to describe and evaluate the quality of care and treatment practices.

Source and reference attributes

Submitting organisation: Cancer Australia

Reference documents: American College of Surgeons 2002. Facility Oncology Registry Data Standards (FORDS), 2009 revision. Commission on Cancer

American College of Surgeons 1998. Standards of the Commission on Cancer: Registry Operations and Data Standards (ROADS), Volume II. Commission on Cancer

Johnson CH & Adamo M (Editors) 2007. SEER Program Coding and Staging Manual 2007, MD 2008 revision. Bethesda:National Cancer Institute, NIH Publication number 07-5581

Relational attributes

Related metadata references:

Has been superseded by [Cancer treatment—other cancer treatment, text X\[X\(149\)\] Health](#), Standard 08/05/2014

See also [Cancer treatment—cancer treatment type, code N\[N\] Health](#), Superseded 08/05/2014

Implementation in Data Set Specifications:

[Cancer \(clinical\) DSS](#)

[Health](#), Superseded 08/05/2014

Conditional obligation: Conditional on the patient having treatment that cannot be defined as surgery, radiotherapy or systemic therapy according to the definitions of those data items in this data set specification.